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impact, price, price against comparator, and innovation. The results in the two disease 
areas were separately analyzed and then compared with each other qualitatively on 
the basis depth of the responses. RESULTS: Awareness about the evidence expecta-
tions were seen to vary substantially between the disease areas. Payers were seen to 
be far more conscious in the high-burden disease area. Of the 12 stakeholders inter-
viewed for the high-burden disease area (cardiovascular disease used as an example), 
all of them could provide an in-depth understanding of the value drivers for a new 
drug. On the other hand, of the stakeholders interviewed from a low-burden disease 
area within urology, a very small part of the sample (n = 2) was able to provide details 
about necessary expectations for the indication. CONCLUSIONS: The variation in 
awareness among payers in disease areas tends to affect the clinical outcomes that are 
presented by the drug manufacturer for a novel drug for the indication. The low 
awareness regarding evidence expectations in disease areas with low budgetary impact 
may lead to lower quality of evidence being accepted for reimbursement. This needs 
to be further investigated. 
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OBJECTIVES: The number of economic-evaluations (EE) increases but their role in 
decision-making remains unclear. Our literature review of the use of EE in decision-
making at macro-level aimed to analyze the methods presented in the articles and to 
investigate differences within and between countries regarding the use of EE, its facili-
tators and barriers. METHODS: We searched major databases (PubMed, Web-of-
Science, Euronheed, EconLit) in seven languages, without time limit, using keywords 
related to economics, health care policy decision-making, and outcomes research. 
Abstracts were screened according to four criteria reﬂ ecting the objectives of our 
review. Selected articles were analyzed and compared using a checklist of items related 
to study context (period, location, domain . . .), methods (population, design . . .), 
and outcomes (use of EE, facilitators, barriers . . .). RESULTS: Twenty-nine articles 
were selected. Most reported single-country- (24), mainly developed-country-studies 
(20). Five multi-country-studies compared countries of Europe, the USA and Latin-
America. The studies’ population generally included public or private health authori-
ties and used questionnaires (10), interviews (6), focus-groups (1), observations (4) or 
a combination of interviews and other methods (8). The main facilitator to using EE 
in decision-making was governmental/institutional incentives (UK and Australia). 
Although the use of EE has increased since the late 1990s, barriers remain, without 
apparent variation, overtime and between countries. Most relate to the accessibility 
and acceptability of EE. CONCLUSIONS: Decision-makers are increasingly aware of 
the importance of using EE in their practice. Despite large differences in the level of 
EE use between countries, barriers are very similar. Studying these barriers could 
narrow gaps between researchers and decision-makers and encourage governmental 
incentives to using EE. Consequently, we decided to develop a methodology for assess-
ing the use of EE in radiotherapy decision-making, a domain where many EE have 
been undertaken, without actually investigating their use. This study will be conducted 
in France, and in European or developing-countries.
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OBJECTIVES: In cost-utility analyses (CUA), utility values are rarely available for the 
entire patients sample and they are generally predicted using a “mapping” interpola-
tion from a functional status questionnaire, known for the entire sample. This 
mapping method is not accounted for in pharmaceutical industry and in literature 
studies, when building conﬁ dence regions around the utility and the incremental cost-
utility ratio, leading to a wrong conﬁ dence region and consequently, to a wrong 
decision-making. The purpose of this paper is to build a conﬁ dence interval (CI) 
around the mean utility, accounting for the uncertainty coming from the “mapping” 
interpolation. METHODS: Analytical and bootstrap methods are developed to handle 
the fact that values are interpolated. Linear, multilinear, and nonlinear mapping are 
considered. Monte Carlo experiments are carried out to compare the performance of 
these methods. These methodologies are applied on data issued from an observational 
study dealing with prostate cancer treatment. Utility is assessed with Standard Gamble 
method and some of these values are interpolated from the questionnaires: EORTC 
QLQC-30; IPSS and IIEF-5; SF-36 and Visual Analogic Scales. RESULTS: Monte 
Carlo experiments show that the analytic and bootstrap 95% CI display coverage 
between 94% and 96% for various sample sizes. If mapping is not accounted for 
(“naive method”), the coverage is between 20% and 40%. The cross validation shows 
similar results. From prostatectomy data, the utility is explained by SF-36, role func-
tioning, diarrhea, and age. For instance, mean utility equals 0.94. The analytic and 
bootstrap CIs equal [0.59, 1.51] and [0.51, 1.63] respectively. The naive interval 
equals [0.95, 1.15]. CONCLUSIONS: In CUA, decision-making based on utility 
values interpolated from mapping is not reliable: a naive interval would lead to a 
serious mistake. The uncertainty due to mapping has to be accounted for. Our analytic 
and bootstrap procedures, integrating the mapping, provide very accurate results.
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BACKGROUND: Two types of mapping exercises have been suggested to translate 
data from the short-form health instrument SF-12 into measurements for the EQ-5D 
instrument. One of the trends associates SF-12 data directly to the EQ-5D index, 
whereas a second approach suggests a response mapping method where SF-12 data 
have been mapped to the ﬁ ve domains of the EQ-5D questionnaire. OBJECTIVES: 
To improve the current response mapping approach and provide a comparison 
between the direct and the response mapping approaches to the EQ-5D. METHODS: 
Five multinomial logit regressions were implemented to estimate the association 
between SF-12 variables and each of the EQ-5D domains. Predicted EQ-5D responses 
were estimated using a Monte Carlo method. a parameter uncertainty approach was 
introduced to calculate conﬁ dence intervals for the predicted EQ-5D index. The direct 
mapping approach for the comparison was also conducted. Several large data sets 
were used for internal and external validation. Actual versus predicted EQ-5D index 
were compared using mean square error (MSE), mean absolute error (MAE), and 
conﬁ dence intervals. RESULTS: In the internal validation data set, both the response 
and direct mapping predicted a similar mean EQ-5D index, but the response mapping 
yielded a smaller MSE of 0.018 compared to 0.020 in the direct mapping, and a 
smaller MAE of 0.091 in the response mapping compared with 0.105 in the direct 
mapping method. Using the external validation data set, the MSE and MAE were one 
decimal point less in the response compared to the direct mapping. CONCLUSIONS: 
The revised response approach provided marginally better results than the direct 
mapping method. The response method can be implemented to country-speciﬁ c 
EQ-5D data with available value sets. To facilitate the implementation of the revised 
response mapping algorithm, a Stata command has been programmed.
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OBJECTIVES: Treatments of ocular hypertension (OHT) and glaucoma aim mainly 
at maintaining the patient’s visual function and related quality of life (QoL). However, 
it is not known to what extent the disease progression impacts the health-related QoL. 
Using recent publications, the objectives were to 1) derive a range of EQ-5D utility 
scores in OHT/glaucoma patients; (2) establish a direct, quantitative link between the 
mean defect in perimetry (MD) measured in decibels (db) and the utility loss; and (3) 
estimate the utility level of patients reaching a glaucoma stage. METHODS: The 
glaucoma stages were characterized using MD thresholds of 0 db (OHT), 0–6 db 
(early glaucoma), 6–12 db (moderate), 12–22 db (advanced), and >22 db (legal blind-
ness), as per the Hodapp classiﬁ cation. An algorithm allowing to derive EQ-5D utility 
scores from the eight mean subscale scores to the SF-36 (Ara and Brazier 2008) was 
applied to the range of SF-36 scores published in a systematic review of QoL in 
glaucoma (Mills 2009). Besides, the same algorithm was used to estimate the utility 
loss corresponding to a MD of 1 db, based on a regression model assessing the correla-
tion between visual function and QoL in glaucoma patients (Lin and Yang 2010). 
RESULTS: Over eight studies in OHT/glaucoma patients, utility scores ranged from 
0.65 to 0.89. Based on a signiﬁ cant regression coefﬁ cient for the SF-36 Role Physical 
subscale, a utility loss of 0.0295/db was calculated. Applying this utility loss/db to the 
predeﬁ ned thresholds, the ranges of unadjusted utility scores expected per glaucoma 
stage equal: 0.72–0.90 (early), 0.55–72 (moderate), 0.25–0.55 (advanced), and <0.25 
(blindness), assuming a baseline utility of 0.90 for OHT. CONCLUSIONS: These 
utility scores per disease stage are consistent with published direct measures of HUI3. 
The estimated utility loss per db is sizeable and could be implemented in cost-utility 
models where disease progression is tracked.
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OBJECTIVES: Anchor-based methods are frequently used for determining the 
minimal important difference (MID) of scales employed to measure patient-reported 
outcomes (PRO). The anchor may, e.g., consist of a global rating by the patient or 
the doctor or of a clinical measure closely related to the issue to be measured. The 
role of the psychometrical properties of the anchor has been rarely studied in this 
context. Aim of this contribution is to shed more light on the relationship between 
